DxPx builds first international Diagnostics Partnering Conference together with MEDICA

Dusseldorf to become globally leading fair location for Diagnostics and Research Tool Industry Startups, corporates and investors from 20 countries already registered

DUSSELDORF, Germany – DxPx Conference, the first international partnering conference for the Diagnostics and Research Tool Industry, has a new strong partner: MEDICA organized by Messe Düsseldorf Group. The international fair company not only organizes the world’s largest medical tradeshow MEDICA but another 13 healthcare events under the international MEDIC Alliance brand, and will now also support DxPx, organized by Silversky LifeScience, to make Dusseldorf a leading business location for diagnostics and research applications. “The MEDICA/DxPx cooperation strengthens the Dusseldorf event venue and creates added business value for our clients”, says Christian Grosser, Deputy Director Global Portfolio Health & Medical Technologies of Messe Düsseldorf. “Every year, on the first day of the MEDICA, exhibitors and visitors with a special interest in diagnostics can now initiate partnering talks in the framework of DxPx Conference to continue their business negotiations on the fairgrounds on the following MEDICA trade days and gather new exhibitor innovation information.”

“With DxPx we address established companies, startups and investors”, says Dr. Mirko Stange, DxPx initiator. “Our partnership with MEDICA also makes DxPx very interesting for participants from Asia and the US.” Partnership with MEDICA adds more convenience and efficiency. All DxPx participants automatically receive a free MEDICA ticket.

Other DxPx Conference sponsors, besides MEDICA, are Roche Diagnostics, Sonic Healthcare’s Bioscientia, business intelligence specialist Research Analytica, Pillar Biosciences, Medicover, and the leading European Hightech Start-up Investor Fund. Talks with additional renowned sponsors are ongoing.

“We have a special offer for startups”, says Dr. Mirko Stange. “In addition to receiving free MEDICA tickets, startups can also send us their short business plan to apply for a free exhibitor booth and one of 15 presenter slots to explain their ideas and products to an international audience.” A jury of sponsors and industry experts will select the presenting startups. Interested startups can upload their business plan at www.dxpx-conference.com.

Oliver Dick

Oliver brings 30+ years of experience in the life sciences industry, has worked in pharma, biotechnology and in vitro diagnostics. His areas of expertise fall under Supply Chain Management, Planning, Production, QC, QA, Engineering, Technology Transfer and Process Improvement. Amongst his vast experience, Oliver held functions such as Vice President of Global Manufacturing at QIAGEN, Chief Operating Officer at Miltenyi Biotec or Chief Operating Office of Resolve Biosciences. He demonstrated exceptional leadership and expertise in driving manufacturing excellence on a global scale.

Oliver has a proven ability to streamline processes, optimize production efficiency, and foster a culture of innovation. He was responsible for strategy development, scaling, cost control and quality and was part of multiple M&A projects and transfer of many new products from acquisition or own development. Today Oliver offers his expertise mainly through his own Consultancy Service Company ODICON.


Christoph Brandenberger is a Managing Director at BGL and a leader in the firm’s Diagnostics, Research Tools & Medical Devices investment banking group. He has more than 20 years of experience in all aspects of mergers and acquisitions, commercialization and partnering agreements, and private placements.

A native of Austria and fluent in German, Christoph’s investment banking experience, coupled with his background in international business, has made him a sought-after advisor in both the domestic and international healthcare markets.

Prior to joining BGL, Christoph served as managing director for Healthios Capital Markets, LLC. Christoph started his career as a financial analyst for Bank of America Securities.


John Riddle

John Riddle is a Managing Director and member of the BGL Executive Committee. He has more than 30 years of investment banking and capital markets experience, advising clients across a broad spectrum of mergers and acquisitions, capital markets activities, and strategic assignments.

John leads BGL’s advisory activities in the Healthcare & Life Sciences investment banking group, which comprises both corporate investment banking and real estate capital markets capabilities. Together with his team, John maintains an ongoing coverage effort with broad activity across several sectors, including health facilities, physician services, and ancillary providers; diagnostics and research tools; medical device and products; and select healthcare technology verticals, including payor services, data analytics, and clinical automation.


Dr. Mirko Stange

Born in Bremen, Germany in 1974, Dr. Mirko Stange is a diagnostics and life sciences expert with a proven track record in turning around and commercializing innovations. He possesses extensive executive management experience, having led diagnostics and biotech startups, as well as developing and conducting consulting products. Following the completion of his Ph.D. in Biochemistry and Biophysics at the University of North Carolina at Chapel Hill, Dr. Stange began his career in 2004 at the strategy consultancy McKinsey. Subsequently, he worked with the turnaround-specialized advisory firm Droege & Comp., primarily serving clients from the pharma and chemistry industry in Germany and Switzerland.

In 2008, he founded an independent Life Sciences consultancy in Germany where, to date, he leads and directs a team of international experts. This team identifies and funds SMEs with high potential for national and international leverage. In addition to his over ten years of experience in independent corporate finance and management consulting, Mirko Stange provides interim management services to selected clients. To date, three companies co-founded and managed/advised by Dr. Stange have been successfully exited. Leveraging his scientific background, he is also a named inventor on several granted and pending patents.


FName LName

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.